[Clinico-biological issues of systemic lupus erythematosus patients].
OBJECTIVE
To investigate clinical and biological aspects and to evaluate potential relation with activity and damage indexes in patients with Systemic Lupus Erythematosus (SLE).


METHODS
Retrospective observational study in 30 consecutive SLE patients (ACR 1997 diagnostic criteria) assessed according to a standard protocol including demographic, clinical and biological (hematology, inflammatory, immunology) data, disease activity (SLEDAI) and damage (SLICC/ACR).


RESULTS
90% SLE women with a mean age of 45.53+13.57 years and a mean age at onset of 31.10 +/- 9.20 years, presenting mainly with skin (43.33%) and small joint (56.66%) involvement, but also with renal (26.66%), cardio-vascular (26.66%) and neurological (6.66%); high anti-DNA double stranded antibodies (30% cases; mean 40.63 +/- 71.62IU/L) and low C3 levels (26.66%; mean 100.63 +/- 26.06 IU/L) have been reported, while more than 76% SLE patients displayed a low disease activity (mean SLEDAI 4 +/- 3.64) and limited damage (mean SLICC/ACR 1.4 +/- 0.85). Statistically significant correlation (p < 0.05) have been identified between SLEDAI and SLICC/ACR (r = 0.477), anti-DNA double stranded and SLEDAI (r = 0.515) respectively SLICC/ACR (r = 0.404), age at onset respectively current age and SLICC/ACR (r1 = 0.495, r2 = 0.468).


CONCLUSIONS
The clinical and biological study based on data from consecutive SLE patients has offered a comprehensive approach of different disease subtypes in North-East Romania. The predominance of currently low disease activity and minimal damage disease profile could reflect either SLE particularities or the expected effects of early individualized therapy.
Facultatea de Medicină, Universităţii de Medicină si Farmacie "Grigore T. Popa", Iaşi.
Iulia Codruţa
IC
Belibou
Codrina
C
Ancuţa
Smaranda
S
Miu
E
E
Ancuţa
Carmen
C
Păstrăguş
Rodica
R
Chirieac
D017677:Age Distribution; D017668:Age of Onset; D000465:Algorithms; D000974:Antibodies, Antinuclear / Q000097:blood; D001168:Arthritis / Q000209:etiology; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000209:etiology; D005076:Exanthema / Q000209:etiology; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000097:blood; D007674:Kidney Diseases / Q000209:etiology; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000209:etiology; D015995:Prevalence; D011788:Quality of Life; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012383:Romania / Q000453:epidemiology; D012720:Severity of Illness Index; D017678:Sex Distribution
D000974:Antibodies, Antinuclear; D015415:Biomarkers; D007155:Immunologic Factors